SCHEMBL2863781

SCHEMBL2863781

CC(C)C[C@@H]1NC(=O)CNC1=O

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ITGB3 P05106 3/20 0.41
ITGA2B P08514 1/20 0.41
ITGAV P06756 6/20 0.37
HDAC1 Q13547 2/20 0.36
F2 P00734 1/20 0.36
PRSS1 P07477 1/20 0.36
PRSS2 P07478 1/20 0.36
PRSS3 P35030 1/20 0.36
GAA P10253 2/20 0.36
LMNA P02545 1/20 0.36
CYP3A4 P08684 1/20 0.36
CYP2C9 P11712 1/20 0.36
CYP2C19 P33261 1/20 0.36
HRH3 Q9Y5N1 2/20 0.35
ITGB8 P26012 4/20 0.34
MEN1 O00255 1/20 0.34
KMT2A Q03164 1/20 0.34
KEAP1 Q14145 1/20 0.33
ITGB6 P18564 1/20 0.33
GHSR Q92847 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6438511 1.00 ITGB3 (0.41) ITGB3ITGA2BITGAVHDAC1F2
SCHEMBL31399270 0.81 KEAP1 (0.44) ITGB3ITGA2BITGAVHDAC1KEAP1
SCHEMBL30695101 0.78 ITGB3 (0.51) ITGB3ITGA2BITGAVITGB8KEAP1
SCHEMBL417814 0.78 HRH3 (0.37) ITGB3ITGA2BITGAVCYP2C9CYP2C19
SCHEMBL6948618 0.78 HRH3 (0.37) ITGB3ITGA2BITGAVCYP2C9CYP2C19
SCHEMBL29375200 0.78 PSMB11 (0.46) ITGB3ITGA2BITGAVHDAC1GHSR
SCHEMBL163425 0.77 MEN1 (0.41) GAALMNACYP3A4CYP2C9CYP2C19
SCHEMBL2867325 0.77 MEN1 (0.41) GAALMNACYP3A4CYP2C9CYP2C19
SCHEMBL4410585 0.75 HRH3 (0.38) ITGB3ITGA2BITGAVHRH3GHSR
SCHEMBL4402037 0.75 HRH3 (0.38) ITGB3ITGA2BITGAVHRH3GHSR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-120131737-A Composition for improving immunity based on astragalus natural ingredients and preparation method thereof 蔓泰(北京)健康科技有限责任公司 2025-06-13 CN claimed
EP-1515684-B1 CARE AND/OR MAKE-UP COSMETIC COMPOSITION STRUCTURED WITH SILICONE POLYMERS AND ORGANOGELLING AGENTS, IN RIGID FORM OREAL (FR) 2010-05-19 EP claimed
US-20050245673-A1 Care and/or make-up cosmetic composition structured with silicone polymers and organogelling agents, in rigid form L'OREAL S.A. (FR) 2005-11-03 US claimed
EP-4743102-A1 COLLAGEN PEPTIDE COMPOSITION AND USE THEREOF IN AMELIORATING NEUROLOGICAL CONDITIONS AND FIBROSIS Rousselot BV (BE) 2026-05-20 EP disclosed
US-12433949-B2 Sustained release delivery systems comprising traceless linkers NOVARTIS AG (CH) 2025-10-07 US disclosed
EP-4594325-A1 PEG-MODIFIED CYCLIC DIPEPTIDES Novmetapharma Co., Ltd. (KR) 2025-08-06 EP disclosed
CN-120131737-A Composition for improving immunity based on astragalus natural ingredients and preparation method thereof 蔓泰(北京)健康科技有限责任公司 2025-06-13 CN disclosed
WO-2025070711-A1 AFLATOXIN PRODUCTION-INHIBITING BACTERIUM, AFLATOXIN PRODUCTION INHIBITOR PRODUCED BY AFLATOXIN PRODUCTION-INHIBITING BACTERIUM AND METHOD FOR PRODUCING SAME, AND METHOD FOR CONTROLLING AFLATOXIN CONTAMINATION USING SAID BACTERIUM OR SAID INHIBITOR 学校法人帝京大学 2025-04-03 WO disclosed
US-20240374689-A1 HIGHLY ACTIVE POLYPEPTIDES AND METHODS OF MAKING AND USING THE SAME LONGEVITY BIOTECH, INC. 2024-11-14 US disclosed
US-20240140955-A1 PEG-MODIFIED CYCLIC DIPEPTIDES NOVMETAPHARMA CO., LTD. (KR) 2024-05-02 US disclosed
WO-2024069524-A1 PEG-MODIFIED CYCLIC DIPEPTIDES NOVMETAPHARMA CO., LTD. (KR) 2024-04-04 WO disclosed
US-20230201353-A1 SUSTAINED RELEASE DELIVERY SYSTEMS COMPRISING TRACELESS LINKERS NOVARTIS AG (CH) 2023-06-29 US disclosed
US-11382911-B2 Plant extract containing diketopiperazine and method for producing same SUNTORY HOLDINGS LIMITED (JP) 2022-07-12 US disclosed
US-7820146-B2 Care and/or make-up cosmetic composition structured with silicone polymers and organogelling agents, in rigid form L'OREAL S.A. (FR) 2010-10-26 US disclosed
EP-1515684-B1 CARE AND/OR MAKE-UP COSMETIC COMPOSITION STRUCTURED WITH SILICONE POLYMERS AND ORGANOGELLING AGENTS, IN RIGID FORM OREAL (FR) 2010-05-19 EP disclosed
US-20050245673-A1 Care and/or make-up cosmetic composition structured with silicone polymers and organogelling agents, in rigid form L'OREAL S.A. (FR) 2005-11-03 US disclosed
US-20050077648-A1 Solution casting method and polymer film FUJIFILM CORPORATION (JP) 2005-04-14 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230201353-A1 SUSTAINED RELEASE DELIVERY SYSTEMS COMPRISING TRACELESS LINKERS ABCB11, ABCB1, GHRHR ITGB3 2109/4885ITGA2B 1894/4885ITGAV 2740/4885
US-20240140955-A1 PEG-MODIFIED CYCLIC DIPEPTIDES LNPEP, ANPEP, DNPEP ITGB3 4069/4885ITGA2B 3869/4885ITGAV 3423/4885
US-12433949-B2 Sustained release delivery systems comprising traceless linkers ABCB11, ABCB1, GHRHR ITGB3 2109/4885ITGA2B 1894/4885ITGAV 2740/4885
US-20240374689-A1 HIGHLY ACTIVE POLYPEPTIDES AND METHODS OF MAKING AND USING THE SAME SCTR, GIPR, APLNR ITGB3 1410/4885ITGA2B 1710/4885ITGAV 1423/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.